Executive SummaryChemex is evaluating Upjohn's Trobicin (spectinomycin) and Cytosar-U (cytarabine) for development as dermatological antivirals to treat infections, warts, and acne, under an agreement announced Jan. 6. Chemex could begin clinicals "as early as April." Trobicin is marketed for gonorrhea; Cytosar-U is indicated for leukemia.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.